Order Article Reprints

Martín Roldán A, Sánchez Suárez MDM, Alarcón-Payer C, Jiménez Morales A, Puerta Puerta JM. A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. Pharmaceutics. 2023; 15(5):1363. https://doi.org/10.3390/pharmaceutics15051363

Martín Roldán, Alicia, María Del Mar Sánchez Suárez, Carolina Alarcón-Payer, Alberto Jiménez Morales, and José Manuel Puerta Puerta. 2023. "A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia" Pharmaceutics 15, no. 5: 1363. https://doi.org/10.3390/pharmaceutics15051363

Martín Roldán, A., Sánchez Suárez, M. D. M., Alarcón-Payer, C., Jiménez Morales, A., & Puerta Puerta, J. M. (2023). A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia. Pharmaceutics, 15(5), 1363. https://doi.org/10.3390/pharmaceutics15051363